CLINICAL TRIALS PROFILE FOR STIVARGA
✉ Email this page to a colleague
All Clinical Trials for STIVARGA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01068769 ↗ | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | Completed | Bayer | Phase 2 | 2010-02-01 | The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study. |
| NCT01068769 ↗ | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | Completed | Brigham and Women's Hospital | Phase 2 | 2010-02-01 | The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study. |
| NCT01068769 ↗ | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | Completed | Fox Chase Cancer Center | Phase 2 | 2010-02-01 | The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study. |
| NCT01068769 ↗ | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | Completed | Massachusetts General Hospital | Phase 2 | 2010-02-01 | The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for STIVARGA
Condition Name
Clinical Trial Locations for STIVARGA
Trials by Country
Clinical Trial Progress for STIVARGA
Clinical Trial Phase
Clinical Trial Sponsors for STIVARGA
Sponsor Name
